| Feb-25-20 09:00AM | GlycoMimetics to Present at the Cowen and Company 40th Annual Health Care Conference 2020 Business Wire |
| Feb-11-20 07:23AM | The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga |
| Feb-06-20 10:40AM | Wall Street Pros: These 3 Stocks Can Double Next Year TipRanks |
| Feb-04-20 09:53AM | GlycoMimetics Advances GMI-1359 Program With Patent Issuance and FDA Designations Business Wire |
| Jan-30-20 09:00AM | First Patient With Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359 Business Wire |
| Jan-06-20 05:14PM | Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug. American City Business Journals |
| 03:02PM | Md. biotech outlines path for blood cancer drug, including in China American City Business Journals |
| 09:00AM | GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China Business Wire |
| Dec-19-19 11:09AM | Hedge Funds Dropped The Ball On GlycoMimetics, Inc. (GLYC) Insider Monkey |
| Nov-29-19 09:41AM | GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019 Business Wire |
| Nov-15-19 08:29PM | Edited Transcript of GLYC earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents |
| Nov-13-19 09:00AM | GlycoMimetics to Present at Two Upcoming Investor Conferences Business Wire +5.03% |
| Nov-08-19 08:00AM | Pharma Sector Tops in October: Best ETFs & Stocks Zacks |
| Nov-07-19 08:24AM | GlycoMimetics Reports Third Quarter 2019 Financial Results and Recent Operational Developments Business Wire +6.05% |
| Nov-06-19 10:03AM | GlycoMimetics to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at 61st ASH Meeting Business Wire |
| Oct-31-19 04:15PM | GlycoMimetics to Report Third Quarter 2019 Financial Results on November 7, 2019 Business Wire -5.21% |
| Oct-30-19 05:23PM | GlycoMimetics, Inc. (GLYC) Is Burning These Hedge Funds Insider Monkey +7.74% |
| Sep-19-19 01:08PM | GlycoMimetics, Inc.'s (NASDAQ:GLYC) Single Biggest Risk For Investors Simply Wall St. |
| Aug-27-19 01:59AM | Edited Transcript of GLYC earnings conference call or presentation 1-Aug-19 12:30pm GMT Thomson Reuters StreetEvents |
| Aug-18-19 06:25PM | Analysts Recommend These 2 Falling Knives GuruFocus.com |
| Aug-08-19 09:00AM | Are Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock? Zacks |
| Aug-05-19 12:21PM | A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019 Benzinga -69.33% |
| 08:56AM | GlycoMimetics stock down 53% after Phase 3 trial failure MarketWatch |
| 06:34AM | GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails TheStreet.com |
| Aug-02-19 08:43PM | GlycoMimetics Reports Top-line Results From Pfizers Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease Business Wire |
| 07:24AM | GlycoMimetics (GLYC) Q2 2019 Earnings Call Transcript Motley Fool |
| Jul-25-19 09:00AM | GlycoMimetics to Report Second Quarter 2019 Financial Results on August 1, 2019 Business Wire |
| Jul-23-19 10:23AM | GlycoMimetics Enters Oversold Territory Zacks |
| May-29-19 04:00PM | GlycoMimetics to Present at Jefferies 2019 Healthcare Conference Business Wire |
| May-20-19 05:15PM | Edited Transcript of GLYC earnings conference call or presentation 2-May-19 12:30pm GMT Thomson Reuters StreetEvents |
| May-11-19 01:27PM | Heres What Hedge Funds Think About GlycoMimetics, Inc. (GLYC) Insider Monkey |
| May-06-19 09:00AM | GlycoMimetics, Inc. Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease Business Wire +5.21% |
| May-04-19 04:23PM | GlycoMimetics (GLYC) Q1 2019 Earnings Call Transcript Motley Fool |
| May-02-19 08:27AM | GlycoMimetics: 1Q Earnings Snapshot Associated Press |
| 07:00AM | GlycoMimetics Reports First Quarter 2019 Results and Recent Operational Highlights Business Wire |
| 06:30AM | GlycoMimetics, Inc. to Host Earnings Call ACCESSWIRE |
| Apr-29-19 04:00PM | GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel Business Wire |
| Apr-25-19 04:00PM | GlycoMimetics to Report First Quarter 2019 Financial Results on May 2, 2019 Business Wire |
| Apr-23-19 09:15AM | GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML Business Wire |
| Apr-22-19 09:00AM | GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359 Business Wire |
| Apr-21-19 01:37AM | Edited Transcript of GLYC earnings conference call or presentation 6-Mar-19 1:30pm GMT Thomson Reuters StreetEvents |
| Apr-12-19 09:00AM | GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359 Business Wire |
| Apr-04-19 04:00PM | GlycoMimetics to Present at Upcoming Investor Conferences Business Wire |
| Mar-07-19 05:30PM | GlycoMimetics to Present at the Cowen and Company 39th Annual Health Care Conference 2019 Business Wire |
| Mar-06-19 02:46PM | Did GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Sell Shares? Simply Wall St. |
| 12:56PM | GlycoMimetics Inc (GLYC) Q4 2018 Earnings Conference Call Transcript Motley Fool |
| 07:30AM | GlycoMimetics Reports Fourth Quarter and Year-End 2018 Results Business Wire |
| 06:30AM | GlycoMimetics, Inc. to Host Earnings Call ACCESSWIRE |
| Mar-05-19 04:30PM | GlycoMimetics Announces Transition Plan for Board of Directors Business Wire |
| Feb-27-19 04:30PM | GlycoMimetics to Report Fourth Quarter and Year-End 2018 Financial Results on March 6, 2019 Business Wire |
| Feb-11-19 08:15AM | Detailed Research: Economic Perspectives on Waddell & Reed Financial, Kennametal, Automatic Data Processing, Trustmark, Eagle Bulk Shipping, and GlycoMimetics What Drives Growth in Today's Competitive Landscape GlobeNewswire |
| Dec-12-18 10:46AM | Heres What We Think About GlycoMimetics, Inc.s (NASDAQ:GLYC) CEO Pay Simply Wall St. |
| Dec-04-18 07:00AM | GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates Business Wire -5.55% |
| Dec-03-18 07:00AM | GlycoMimetics Presents New AML Data with Uproleselan at 60th ASH Annual Meeting Business Wire |
| Nov-29-18 09:15AM | GlycoMimetics to Host 2018 Investor/Analyst Meeting at 60th ASH Annual Meeting on December 3, 2018 Business Wire -5.61% |
| Nov-28-18 09:00AM | Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors Business Wire +5.21% |
| Nov-27-18 07:15AM | 3 Top Biotech Stocks to Buy Right Now Motley Fool -8.93% |
| Nov-19-18 09:00AM | GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia Business Wire |
| Nov-16-18 03:27AM | Edited Transcript of GLYC earnings conference call or presentation 2-Nov-18 12:30pm GMT Thomson Reuters StreetEvents |
| Nov-06-18 07:40AM | Report: Developing Opportunities within Stryker, Anavex Life Sciences, Engility, Baker Hughes, a GE company, GlycoMimetics, and HCP Future Expectations, Projections Moving into 2018 GlobeNewswire |
| Nov-02-18 07:39AM | GlycoMimetics: 3Q Earnings Snapshot Associated Press |
| 07:30AM | GlycoMimetics Reports Third Quarter 2018 Results and Highlights Recent Company Achievements Business Wire |
| Nov-01-18 09:58AM | GlycoMimetics to Present Analyses from Phase 1/2 AML Trial of Uproleselan at 60th ASH Meeting Business Wire |
| Oct-26-18 09:00AM | GlycoMimetics to Report Third Quarter 2018 Financial Results on November 2, 2018 Business Wire |
| Oct-24-18 09:00AM | GlycoMimetics to Present at Upcoming Investor Conferences Business Wire -13.47% |
| Oct-10-18 04:54PM | Neurocrine Inks Deal with Private Biotech to Make CNS Drugs Zacks |
| Aug-31-18 07:45AM | Research Report Identifies FS Investment, Rush Enterprises, GlycoMimetics, Federal Signal, ATN International, and Novavax with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire |
| Aug-29-18 04:00AM | Edited Transcript of GLYC earnings conference call or presentation 10-Aug-18 12:30pm GMT Thomson Reuters StreetEvents |
| Aug-14-18 09:00AM | GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271) Business Wire |
| Aug-10-18 10:15PM | GlycoMimetics (GLYC) Q2 2018 Earnings Conference Call Transcript Motley Fool |
| 03:17PM | GlycoMimetics Stock Has Substantial Upside InvestorPlace |
| 06:30AM | GlycoMimetics, Inc. to Host Earnings Call ACCESSWIRE |
| Aug-09-18 04:49PM | GlycoMimetics: 2Q Earnings Snapshot Associated Press |
| 04:05PM | GlycoMimetics Reports Second Quarter 2018 Results and Highlights Recent Company Achievements Business Wire |
| Aug-02-18 09:00AM | GlycoMimetics to Report Second Quarter 2018 Financial Results on August 9, 2018 Business Wire |
| Jul-27-18 07:50AM | Factors of Influence in 2018, Key Indicators and Opportunity within Minerals Technologies, USG, Continental Resources, Take-Two Interactive Software, Trimble, and GlycoMimetics New Research Emphasizes Economic Growth GlobeNewswire |
| Jul-18-18 07:20AM | Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks ACCESSWIRE |
| Jun-14-18 07:05AM | Free Technical Reports on Gilead Sciences and Three Additional Biotech Equities ACCESSWIRE -6.06% |
| Jun-01-18 04:15PM | GlycoMimetics to Present at Jefferies 2018 Global Healthcare Conference Business Wire |
| May-30-18 09:15AM | GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Business Wire |
| May-22-18 08:15AM | New Research Coverage Highlights Apollo Commercial Real Estate Finance, Drive Shack, GlycoMimetics, Dycom Industries, Apple Hospitality REIT, and Howard Hughes Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
| May-03-18 04:05PM | Edited Transcript of GLYC earnings conference call or presentation 3-May-18 12:30pm GMT Thomson Reuters StreetEvents -6.49% |
| 08:46AM | GlycoMimetics: 1Q Earnings Snapshot Associated Press |
| 07:00AM | GlycoMimetics Reports First Quarter 2018 Results Business Wire |
| Apr-26-18 09:00AM | GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018 Business Wire |
| Mar-29-18 08:20AM | New Research Coverage Highlights Healthcare Trust of America, Drive Shack, Chemed, AMERISAFE, Medical Properties Trust, and GlycoMimetics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
| Mar-20-18 09:24PM | GlycoMimetics Announces Pricing of Public Offering of Common Stock Business Wire |
| Mar-19-18 04:01PM | GlycoMimetics Announces Proposed Public Offering of Common Stock Business Wire -5.73% |
| Mar-14-18 05:55PM | GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018 Business Wire |
| Mar-07-18 09:00AM | GlycoMimetics to Present at Four Investor Conferences This Month Business Wire |
| Mar-06-18 10:16PM | Edited Transcript of GLYC earnings conference call or presentation 6-Mar-18 1:30pm GMT Thomson Reuters StreetEvents -17.84% |
| 02:48PM | Why GlycoMimetics Is Tumbling 19.2% Today Motley Fool |
| 08:30AM | Todays Research Reports on Trending Tickers: GlycoMimetics, Inc. and Vericel Corporation ACCESSWIRE |
| 07:51AM | GlycoMimetics reports 4Q loss Associated Press |
| 07:30AM | GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results Business Wire |
| 06:00AM | GlycoMimetics, Inc. to Host Earnings Call ACCESSWIRE |
| Mar-05-18 04:01PM | GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML Business Wire -5.90% |
| 01:39PM | When Can We Expect A Profit From GlycoMimetics Inc (NASDAQ:GLYC)? Simply Wall St. |
| 08:35AM | Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? Zacks |
| Feb-27-18 09:00AM | GlycoMimetics to Report Fourth Quarter and Year-End 2017 Financial Results on March 6, 2018 Business Wire |
